A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

• Status: Active, not recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Albumin-Bound Paclitaxel; Antibodies, Monoclonal; Fluorouracil; Gemcitabine; Irinotecan; Leucovorin; Nivolumab; Oxaliplatin; Paclitaxel

Criteria

Inclusion Criteria:

• Must have histological or cytological confirmed diagnosis of locally advanced or metastatic adenocarcinoma of the pancreas, which has progressed on or after one line of chemotherapy

• ECOG Performance status 0-1

• Adequate organ functions

• Measurable disease

Exclusion Criteria:

• Suspected or known CNS metastasis

• Participants with active, known, or suspected autoimmune disease

• Uncontrolled or significant cardiovascular disease

• Prior exposure to selected immune cell-modulating antibody regimens